Literature DB >> 28741229

Inhaled Antimicrobials for Ventilator-Associated Pneumonia: Practical Aspects.

Garyphallia Poulakou1, Dimitrios K Matthaiou2, David P Nicolau3, Georgios Siakallis4, George Dimopoulos2.   

Abstract

Positive experience with inhaled antibiotics in pulmonary infections of patients with cystic fibrosis has paved the way for their utilization in mechanically ventilated, critically ill patients with lower respiratory tract infections. A successful antibiotic delivery depends upon the size of the generated particle and the elimination of drug impaction in the large airways and the ventilator circuit. Generated droplet size is mainly affected by the type of the nebulizer employed. Currently, jet, ultrasonic, and vibrating mesh nebulizers are marketed; the latter can deliver optimal antibiotic particle size. Promising novel drug-device combinations are able to release drug concentrations of 25- to 300-fold the minimum inhibitory concentration of the targeted pathogens into the pulmonary alveoli. The most important practical steps of nebulization include pre-assessment and preparation of the patient (suctioning, sedation, possible bronchodilation, adjustment of necessary ventilator settings); adherence to the procedure (drug preparation, avoidance of unnecessary tubing connections, interruption of heated humidification, removal of heat-moisture exchanger); inspection of the procedure (check for residual in drug chamber, change of expiratory filter, return sedation, and ventilator settings to previous status); and surveillance of the patient for adverse events (close monitoring of the patient and particularly of peak airway pressure and bronchoconstriction). Practical aspects of nebulization are very important to ensure optimal drug delivery and safe procedure for the patient. Therefore, the development of an operational checklist is a priority for every department adopting this modality.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28741229     DOI: 10.1007/s40265-017-0787-0

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  92 in total

1.  Bronchoconstriction following nebulised colistin in cystic fibrosis.

Authors:  S Cunningham; A Prasad; L Collyer; S Carr; I B Lynn; C Wallis
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Aerosol polymyxin and pneumonia in seriously ill patients.

Authors:  T W Feeley; G C Du Moulin; J Hedley-Whyte; L S Bushnell; J P Gilbert; D S Feingold
Journal:  N Engl J Med       Date:  1975-09-04       Impact factor: 91.245

3.  Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study.

Authors:  I P Korbila; A Michalopoulos; P I Rafailidis; D Nikita; G Samonis; M E Falagas
Journal:  Clin Microbiol Infect       Date:  2009-09-02       Impact factor: 8.067

Review 4.  Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents.

Authors:  Keith A Rodvold; Jomy M George; Liz Yoo
Journal:  Clin Pharmacokinet       Date:  2011-10       Impact factor: 6.447

5.  Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens.

Authors:  A Bruce Montgomery; Paul R Rhomberg; Tammy Abuan; Kathie-Anne Walters; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

6.  Nebulized colistin causes chest tightness in adults with cystic fibrosis.

Authors:  J Maddison; M Dodd; A K Webb
Journal:  Respir Med       Date:  1994-02       Impact factor: 3.415

Review 7.  Ventilatory strategies in obstructive lung disease.

Authors:  Francisco José Parrilla; Indalecio Morán; Ferran Roche-Campo; Jordi Mancebo
Journal:  Semin Respir Crit Care Med       Date:  2014-08-11       Impact factor: 3.119

8.  Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multidrug-resistant Gram-negative bacilli with inhaled polymyxin B.

Authors:  Graziella H Pereira; Patrícia R Muller; Anna S Levin
Journal:  Diagn Microbiol Infect Dis       Date:  2007-03-09       Impact factor: 2.803

9.  Lung distribution and pharmacokinetics of aerosolized tobramycin.

Authors:  P Le Conte; G Potel; P Peltier; D Horeau; J Caillon; M E Juvin; M F Kerguéris; D Bugnon; D Baron
Journal:  Am Rev Respir Dis       Date:  1993-05

10.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Authors:  Fabio Ferrari; Qin Lu; Cassio Girardi; Olivier Petitjean; Charles-Hugo Marquette; Frederic Wallet; Jean-Jacques Rouby
Journal:  Intensive Care Med       Date:  2009-08-04       Impact factor: 17.440

View more
  1 in total

Review 1.  Aerosolized antibiotics for ventilator-associated pneumonia: a pairwise and Bayesian network meta-analysis.

Authors:  Feng Xu; Lu-Lu He; Luan-Qing Che; Wen Li; Song-Min Ying; Zhi-Hua Chen; Hua-Hao Shen
Journal:  Crit Care       Date:  2018-11-15       Impact factor: 9.097

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.